Bruker Daltonics Introduces Unique Focus Option For ESI-TOF.Business Editors/Health/Medical Writers/High-Tech Writers Pittcon 2004 CHICAGO--(BUSINESS WIRE)--March 8, 2004 MicroTOF(TM) with 15k Resolution Significantly Outperforms all other Bench-Top ESI-TOF Mass Spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. Systems At the 2004 Pittsburgh Conference in Chicago, Bruker Daltonics Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), today announced Focus(TM), a novel technology (patent applied for) for increasing the resolution of ESI-TOF systems significantly. The Company's new bench-top electrospray ionization time-of-flight (ESI-TOF) mass spectrometer, called microTOF(TM), was introduced in 2003. It has quickly become the preferred high-performance choice for customers performing demanding research in drug development, metabonomics, discovery of peptide biomarkers, combichem analysis, etc. with robust, compact bench-top ESI-TOF systems. The microTOF system achieves 10k resolution and robust 3 ppm mass accuracy without resorting to so-called W-reflection, during which typically more than 70% of the ions to be measured are lost, compared to normal V-reflection operation. Such an ion signal loss to gain resolution is unacceptable for most customers and applications. The new Focus technology, available as a cost-effective $20,000 factory-option for new systems purchases, enables superior resolution of 15k across essentially the entire mass spectrum. With the Focus option, the microTOF is the unrivalled performance leader in the bench-top ESI-TOF market, outperforming most floor-standing Q-q-TOF type instruments in terms of resolution. Dr. Michael Schubert, Managing Director for R&D at Bruker Daltonik GmbH, explained: "As the Focus technology utilizes multiple advances in time-of-flight ion optics and ion detection, and not W-reflection, it does not suffer from any loss of ion transmission. We believe the Focus capability will be very useful for customers performing drug development, academic or clinical research. It is available for new systems orders effective immediately." For pharmaceutical customers, the microTOF system offers software tools to support customers in achieving 21 CFR CFR See: Cost and Freight Part 11 compliance. Bruker Daltonics also offers optional IQ, OQ and PV services to FDA-regulated customers. ABOUT BRUKER BIOSCIENCES Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion